Latest Medtech News
This week brought fresh capital across some of MedTech’s most active areas. Funding went toward AI-powered monitoring and diagnostics, interventional technologies, surgical robotics, senior care and smart hearing solutions, with companies using new investment to advance development and commercial growth.
As an executive search partner to the MedTech industry, Guided Solutions keeps a close eye on stories like these. Subscribe to our Industry Insights for weekly coverage.
Inspiren raises $70M Series C to scale AI-powered senior living
Inspiren has raised $70M in Series C funding, bringing its total funding to $225M at a valuation exceeding $500M. The funding will support expansion of its AI-powered physical care platform, including its hardware ecosystem and go-to-market efforts across senior living communities.
Founder and Chief Clinical Officer Michael Wang: "A decade from now, no one will accept that a resident's needs could go unknown behind a closed door. We are already making that unthinkable in the communities we serve, and this funding puts it within reach for many more,"
Kossel Medtech raises $60M Series C to expand interventional devices
Kossel Medtech has raised $60M in Series C funding, led by Shenzhen Capital Group and Jinhe Capital, bringing in both new and existing investors. The funding will support production expansion, R&D and global regulatory registration across its peripheral and coronary intervention and cardiac electrophysiology portfolios.
Founder and CEO Hu Qing
Implicity raises $40M to expand AI-powered cardiac monitoring
Implicity has raised $40M in funding, led by IRIS with participation from Five Arrows. The funding will support U.S. commercial expansion, growth across Europe and further investment in AI, including next-generation heart failure prediction algorithms.
Founder and CEO Arnaud Rosier
Neurent Medical secures €25M growth debt financing
Neurent Medical has secured a €25M growth debt facility from Claret Capital Partners, following its €62.5M Series C earlier this year. The financing will support commercial expansion, sales and marketing, and the continued U.S. rollout of NEUROMARK®, while providing additional financial flexibility with minimal dilution to shareholders.
CEO Brian Shields: “We are delighted to deepen our relationship with Claret Capital Partners, whose continued support reflects confidence in our technology, clinical evidence, commercial progress and long-term vision."
Deneb Medical closes €14.7M round to advance IZAR spine robotics platform
Deneb Medical has closed a €14.7M funding round to advance the development and commercial launch of IZAR, its robotic spine surgery platform. The funding will support market launch, team growth and further development of the system, which combines robotics, photonics and AI for spinal procedures.
Co-Founders Aritz Lazkoz and Juan Arregui Altuna
DermaSensor raises $5M to expand AI skin cancer diagnostics
DermaSensor has raised $5M in a Series B extension, bringing total funding to approximately $48M. The financing follows four new commercial partnerships, including Henry Schein, and will support the broader U.S. rollout of its AI-powered device for assessing suspicious skin lesions.
CEO Cody Simmons: “Our professional investor partners have supported us through every phase of building this new medical device category."
Elehear raises $4.5M Series A extension to advance smart hearing technology
Elehear has raised $4.5M in a Series A extension, led by C Capital. The funding will support further development of its smart hearing technology, combining personalised sound processing, voice enhancement and voice interaction to improve speech clarity in noisy environments.
Founder and CEO Eric Miao
Healthplus.ai extends Seed round to €3.3M
Healthplus.ai has extended its Seed round to €3.3M, with new investment from BVP and Noso Capital alongside existing backers. The funding will support the European rollout of PERISCOPE, its AI-based software for predicting post-surgical infection risk, while expanding into other complications and advancing its U.S. FDA pathway.
Founder and CEO Bart Geerts
